Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: Analysis of prospective randomised phase III trials
European Journal of Cancer2012Vol. 49(1), pp. 142–149
Citations Over TimeTop 10% of 2012 papers
Sven� Mahner, Christine zu Eulenburg, A. Staehle, Karl Wegscheider, A. Reuss, Éric Pujade-Lauraine, Philipp Harter, Isabelle Ray‐Coquard, Jacobus Pfisterer, Andreas du Bois
Related Papers
- → MicroRNA‐135a‐3p as a promising biomarker and nucleic acid therapeutic agent for ovarian cancer(2017)55 cited
- → circKIF4A sponges miR-127 to promote ovarian cancer progression(2020)24 cited
- → Thioredoxin 1 as a serum marker for ovarian cancer and its use in combination with CA125 for improving the sensitivity of ovarian cancer diagnoses(2014)16 cited
- → Ovarian cancer : state of the art and future directions in translational research(2008)4 cited
- → Ovarian Cancer(2004)2 cited